Document Detail


Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review.
MedLine Citation:
PMID:  23530659     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Previous studies have provided conflicting results regarding the effect of drospirenone-containing oral contraceptive pills (OCPs) on the risk of venous and arterial thrombosis.
OBJECTIVES: To conduct a systematic review to assess the risk of venous thromboembolism (VTE), myocardial infarction (MI), and stroke in individuals taking drospirenone-containing OCPs.
SEARCH STRATEGY: We systematically searched CINAHL, the Cochrane Library, Dissertation & Abstracts, EMBASE, HealthStar, Medline, and the Science Citation Index from inception to November 2012.
SELECTION CRITERIA: We included all case reports, observational studies, and experimental studies assessing the risk of venous and arterial thrombosis of drospirenone-containing OCPs.
DATA COLLECTION AND ANALYSIS: Data were collected independently by two reviewers.
MAIN RESULTS: A total of 22 studies [six case reports, three case series (including 26 cases), and 13 comparative studies] were included in our systematic review. The 32 identified cases suggest a possible link between drospirenone-containing OCPs and venous and arterial thrombosis. Incidence rates of VTE among drospirenone-containing OCP users ranged from 23.0 to 136.7 per 100 000 woman-years, whereas those among levonorgestrel-containing OCP users ranged from 6.64 to 92.1 per 100 000 woman-years. The rate ratio for VTE among drospirenone-containing OCP users ranged from 4.0 to 6.3 compared with non-users of OCPs, and from 1.0 to 3.3 compared with levonorgestrel-containing OCP users. The arterial effects of drospirenone-containing OCPs were inconclusive.
AUTHOR'S CONCLUSIONS: Our systematic review suggests that drospirenone-containing OCP use is associated with a higher risk for VTE than both no OCP use and levonorgestrel-containing OCP use.
Authors:
C Q Wu; S M Grandi; K B Filion; H A Abenhaim; L Joseph; M J Eisenberg
Related Documents :
16001189 - Post-menopausal vaginal angiomyofibroblastoma: a case report.
9804199 - Mesenchymal chondrosarcoma of the jaws. report of four cases.
2671219 - Acinous cell carcinoma of the larynx.
2703539 - Bulky extramedullary plasmacytomata: rare mode of relapse in myelomatosis.
23530659 - Drospirenone-containing oral contraceptive pills and the risk of venous and arterial th...
2667619 - A case of infantile digital fibromatosis showing spontaneous regression.
12596069 - Phimosis as a cause of the prune belly syndrome: comparison to a more common pattern of...
22627459 - Bilateral oncocytoma in the parotid gland.
10683659 - Chronic obstructive pneumonia caused by a vertebral body osteophyte.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-03-26
Journal Detail:
Title:  BJOG : an international journal of obstetrics and gynaecology     Volume:  120     ISSN:  1471-0528     ISO Abbreviation:  BJOG     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-10     Completed Date:  2013-07-01     Revised Date:  2014-07-29    
Medline Journal Info:
Nlm Unique ID:  100935741     Medline TA:  BJOG     Country:  England    
Other Details:
Languages:  eng     Pagination:  801-10     Citation Subset:  AIM; IM    
Copyright Information:
© 2013 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2013 RCOG.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Androstenes / adverse effects*
Arteries
Contraceptives, Oral, Hormonal / adverse effects*
Female
Humans
Myocardial Infarction / chemically induced*
Pulmonary Embolism / chemically induced*
Risk
Stroke / chemically induced*
Thrombosis / chemically induced*
Venous Thromboembolism / chemically induced
Venous Thrombosis / chemically induced
Grant Support
ID/Acronym/Agency:
MOP-119362//Canadian Institutes of Health Research
Chemical
Reg. No./Substance:
0/Androstenes; 0/Contraceptives, Oral, Hormonal; N295J34A25/drospirenone
Comments/Corrections
Comment In:
Evid Based Nurs. 2014 Jul;17(3):71   [PMID:  24170817 ]
BJOG. 2013 Jun;120(7):811   [PMID:  23802311 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of government investment in primary healthcare institutions to promote equity during the th...
Next Document:  Quercetin induces insulin secretion by direct activation of L- type calcium channels in the pancreat...